S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68

NanoString Technologies (NSTG) Stock Forecast, Price & News

+0.07 (+0.44%)
(As of 05/20/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
554,500 shs
Average Volume
751,641 shs
Market Capitalization
$743.12 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive NSTG News and Ratings via Email

Sign-up to receive the latest news and ratings for NanoString Technologies and its competitors with MarketBeat's FREE daily newsletter.

NanoString Technologies logo

About NanoString Technologies

NanoString Technologies, Inc. develops, manufactures, and sells tools for scientific and clinical research in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter MAX and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; panels with oncology, immunology and infectious disease, and neuroscience applications. Further, the company offers Master Kits, such as ancillary reagents and plasticware to setup and process samples in the nCounter Prep Station and nCounter Digital Analyzer; and Prosigna molecular diagnostic test kits. The company is also developing GeoMx DSP system to enable the field of spatial genomics. It has collaboration with Lam Research Corporation for the research and development of Hyb & Seq technologies; Celgene Corporation for developing LymphMark, an in vitro diagnostic for the treatment of diffuse large B-cell lymphoma; and Parker Institute for Cancer Immunotherapy to develop CAR-T regimens that enhances patient outcomes for various types of cancer. NanoString Technologies, Inc. was incorporated in 2003 and is headquartered in Seattle, Washington.


See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$145.09 million
Book Value
$3.13 per share


Net Income
$-115.25 million
Pretax Margin




Free Float
Market Cap
$743.12 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.87 out of 5 stars

Medical Sector

718th out of 1,416 stocks

Biological Products, Except Diagnostic Industry

113th out of 210 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -

NanoString Technologies (NASDAQ:NSTG) Frequently Asked Questions

Is NanoString Technologies a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NanoString Technologies in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NanoString Technologies stock.
View analyst ratings for NanoString Technologies
or view top-rated stocks.

Are investors shorting NanoString Technologies?

NanoString Technologies saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 3,620,000 shares, an increase of 31.2% from the April 15th total of 2,760,000 shares. Based on an average daily trading volume, of 736,200 shares, the short-interest ratio is presently 4.9 days. Currently, 8.1% of the shares of the company are short sold.
View NanoString Technologies' Short Interest

When is NanoString Technologies' next earnings date?

NanoString Technologies is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for NanoString Technologies

How were NanoString Technologies' earnings last quarter?

NanoString Technologies, Inc. (NASDAQ:NSTG) announced its quarterly earnings results on Tuesday, May, 10th. The biotechnology company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.53) by $0.33. The biotechnology company earned $31.08 million during the quarter, compared to the consensus estimate of $30.95 million. NanoString Technologies had a negative trailing twelve-month return on equity of 68.57% and a negative net margin of 87.89%. The firm's revenue for the quarter was down 1.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.62) earnings per share.
View NanoString Technologies' earnings history

What price target have analysts set for NSTG?

4 analysts have issued 12 month price objectives for NanoString Technologies' shares. Their forecasts range from $30.00 to $70.00. On average, they anticipate NanoString Technologies' stock price to reach $45.67 in the next twelve months. This suggests a possible upside of 185.2% from the stock's current price.
View analysts' price targets for NanoString Technologies
or view top-rated stocks among Wall Street analysts.

Who are NanoString Technologies' key executives?
NanoString Technologies' management team includes the following people:
  • Mr. R. Bradley Gray, CEO, Pres & Director (Age 45, Pay $1.14M) (LinkedIn Profile)
  • Mr. K. Thomas Bailey M.B.A., Chief Financial Officer (Age 53, Pay $638.16k) (LinkedIn Profile)
  • Mr. David W. Ghesquiere, Sr. VP of Corp. & Bus. Devel. (Age 55, Pay $598.61k)
  • Dr. Joseph M. Beechem, Chief Scientific Officer and Sr. VP of R&D (Age 64, Pay $615.92k) (LinkedIn Profile)
  • Mr. Mark A. Winham, Sr. VP of Operations
  • Mr. Douglas S. Farrell, VP of Investor Relations & Corp. Communications
  • Ms. Kathryn Surace-Smith, Sr. VP of HR & Legal Affairs and Corp. Sec. (Age 63)
  • Dr. Mary Tedd Allen, Sr. VP of Strategic Initiatives (Age 59)
  • Dr. Philippa Webster Ph.D., Sr. Principal Scientist
  • Mr. John D. Gerace, Chief Commercial Officer
What is Brad Gray's approval rating as NanoString Technologies' CEO?

36 employees have rated NanoString Technologies CEO Brad Gray on Glassdoor.com. Brad Gray has an approval rating of 65% among NanoString Technologies' employees.

What other stocks do shareholders of NanoString Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NanoString Technologies investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Aegean Marine Petroleum Network (ANW), Chipotle Mexican Grill (CMG), Precision Drilling (PD), AutoZone (AZO), Designer Brands (DBI), Bank of the Ozarks (OZRK) and Vista Outdoor (VSTO).

What is NanoString Technologies' stock symbol?

NanoString Technologies trades on the NASDAQ under the ticker symbol "NSTG."

Who are NanoString Technologies' major shareholders?

NanoString Technologies' stock is owned by many different retail and institutional investors. Top institutional investors include Wellington Management Group LLP (11.43%), BlackRock Inc. (9.31%), Vanguard Group Inc. (7.31%), Invesco Ltd. (3.57%), Polar Capital Holdings Plc (3.48%) and Alyeska Investment Group L.P. (3.11%). Company insiders that own NanoString Technologies stock include Charles P Waite Jr, Elisha W Finney, Gregory Norden, J Chad Brown, Joseph M Beechem, K Thomas Bailey, Kirk Malloy, R Bradley Gray and Robert Hershberg.
View institutional ownership trends for NanoString Technologies

Which institutional investors are selling NanoString Technologies stock?

NSTG stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Wellington Management Group LLP, RTW Investments LP, TimesSquare Capital Management LLC, BlackRock Inc., Vanguard Group Inc., Connacht Asset Management LP, and Dimensional Fund Advisors LP. Company insiders that have sold NanoString Technologies company stock in the last year include Elisha W Finney, Joseph M Beechem, K Thomas Bailey, Kirk Malloy, and R Bradley Gray.
View insider buying and selling activity for NanoString Technologies
or view top insider-selling stocks.

Which institutional investors are buying NanoString Technologies stock?

NSTG stock was purchased by a variety of institutional investors in the last quarter, including Polar Capital Holdings Plc, Alyeska Investment Group L.P., Goldman Sachs Group Inc., Invesco Ltd., State Street Corp, Granite Investment Partners LLC, TD Asset Management Inc., and B. Metzler seel. Sohn & Co. AG.
View insider buying and selling activity for NanoString Technologies
or or view top insider-buying stocks.

How do I buy shares of NanoString Technologies?

Shares of NSTG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NanoString Technologies' stock price today?

One share of NSTG stock can currently be purchased for approximately $16.01.

How much money does NanoString Technologies make?

NanoString Technologies has a market capitalization of $743.12 million and generates $145.09 million in revenue each year. The biotechnology company earns $-115.25 million in net income (profit) each year or ($2.79) on an earnings per share basis.

How many employees does NanoString Technologies have?

NanoString Technologies employs 766 workers across the globe.

What is NanoString Technologies' official website?

The official website for NanoString Technologies is www.nanostring.com.

How can I contact NanoString Technologies?

NanoString Technologies' mailing address is 530 FAIRVIEW AVENUE NORTH SUITE 2000, SEATTLE WA, 98109. The biotechnology company can be reached via phone at (888) 358-6266, via email at [email protected], or via fax at 206-378-6288.

This page was last updated on 5/23/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.